Thiard News@F4F

@newsen.bsky.social

4 months ago

Menarini Group Unveils Promising Phase 2 Elacestrant Data at San Antonio Breast Cancer Symposium Menarini Group and Stemline Therapeutics present promising findings on Elacestrant's effectiveness in treating ER+, HER2- metastatic breast cancer at SABCS 2025.

Menarini Group Unveils Promising Phase 2 Elacestrant Data at San Antonio Breast Cancer Symposium #USA #San_Antonio #Elacestrant #Menarini_Group #SABCS_2025

Thiard News@F4F

@newsen.bsky.social

4 months ago

Menarini Group Unveils Significant Data for Elacestrant in ER+ HER2- Metastatic Breast Cancer at SABCS 2025 Discover groundbreaking results from Menarini Group's Elacestrant study for treating ER+, HER2- metastatic breast cancer, showcased at SABCS 2025.

Menarini Group Unveils Significant Data for Elacestrant in ER+ HER2- Metastatic Breast Cancer at SABCS 2025 #USA #New_York #Breast_Cancer #Elacestrant #Menarini_Group

Thiard News@F4F

@newsen.bsky.social

4 months ago

Menarini Group Showcases Promising Elacestrant Data at 2025 SABCS for Breast Cancer Treatment Menarini Group, alongside Stemline Therapeutics, shares promising findings on Elacestrant's efficacy for treating ER+, HER2- metastatic breast cancer at the San Antonio Symposium.

Menarini Group Showcases Promising Elacestrant Data at 2025 SABCS for Breast Cancer Treatment #United_States #San_Antonio #Breast_Cancer #Elacestrant #Menarini_Group

Thiard News@F4F

@newsen.bsky.social

4 months ago

Volpi Rosse Menarini Unveils 'Fantastic Ten' for the 2025-2026 Season The Volpi Rosse Menarini wheelchair basketball team launches its new roster for the upcoming season, vying for glory in Italy and Europe.

Volpi Rosse Menarini Unveils 'Fantastic Ten' for the 2025-2026 Season #Italy #Florence #Menarini_Group #Volpi_Rosse #Basketball_Team

Thiard News@F4F

@newsen.bsky.social

4 months ago

Menarini Group Presents New Data on ELZONRIS at ASH 2025 Annual Meeting Menarini Group and Stemline Therapeutics reveal new findings regarding ELZONRIS® data at the 67th ASH Annual Meeting, highlighting innovative treatments for BPDCN.

Menarini Group Presents New Data on ELZONRIS at ASH 2025 Annual Meeting #USA #Orlando #Menarini_Group #BPDCN #ELZONRIS

Thiard News@F4F

@newsen.bsky.social

4 months ago

Menarini Group Unveils Promising Data for ELZONRIS® at ASH Annual Meeting Menarini Group announces significant results for ELZONRIS® at the upcoming ASH Annual Meeting, highlighting new treatment options for patients with BPDCN.

Menarini Group Unveils Promising Data for ELZONRIS® at ASH Annual Meeting #USA #Orlando #Menarini_Group #BPDCN #ELZONRIS

Thiard News@F4F

@newsen.bsky.social

4 months ago

Menarini Group Unveils Promising Findings on ELZONRIS for BPDCN at ASH Meeting Key new findings on ELZONRIS treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) to be showcased at the 67th American Society of Hematology Annual Meeting in December 2025.

Menarini Group Unveils Promising Findings on ELZONRIS for BPDCN at ASH Meeting #Italy #Florence #Menarini_Group #BPDCN #ELZONRIS

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lusochimica S.p.A. Receives EU STEP Seal for Sustainable Nebivolol Synthesis Project Lusochimica S.p.A., part of Menarini Group, secures the STEP Seal and EU funding for an innovative project to enhance nebivolol synthesis sustainably.

Lusochimica S.p.A. Receives EU STEP Seal for Sustainable Nebivolol Synthesis Project #Italy #Menarini_Group #Lusochimica #Lomagna #nebivolol

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lusochimica S.p.A. Earns European STEP Seal for Eco-Friendly Nebivolol Synthesis Lusochimica S.p.A., part of the Menarini Group, has been awarded the STEP Seal by the European Commission for its innovative SmartNEBI project aimed at sustainable nebivolol synthesis.

Lusochimica S.p.A. Earns European STEP Seal for Eco-Friendly Nebivolol Synthesis #Italy #Menarini_Group #Lusochimica #SmartNEBI #Lomania

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lusochimica S.p.A. Earns European Commission's STEP Seal Award Lusochimica S.p.A. has been awarded the prestigious STEP Seal by the European Commission for excellence in clean technology with its SmartNEBI project.

Lusochimica S.p.A. Earns European Commission's STEP Seal Award #Italy #Menarini_Group #Lomagna #STEP_Seal #Lusochimica_S.p.A

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lusochimica S.p.A. Recognized with European STEP Seal Award for Eco-Friendly Project Lusochimica S.p.A. has been awarded the STEP Seal by the European Commission for its innovative SmartNEBI project, enhancing nebivolol synthesis sustainability.

Lusochimica S.p.A. Recognized with European STEP Seal Award for Eco-Friendly Project #Italy #Menarini_Group #Lusochimica #SmartNEBI #Lomagna

Thiard News@F4F

@newsen.bsky.social

7 months ago

Menarini Group Seeks EMA Approval for Obicetrapib Treatments for Cholesterol Management Menarini Group's request to EMA for the registration of Obicetrapib aims to provide new treatment options for patients with primary hypercholesterolemia. This could potentially enhance cholesterol management in patients unable to achieve target levels.

Menarini Group Seeks EMA Approval for Obicetrapib Treatments for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Thiard News@F4F

@newsen.bsky.social

7 months ago

Menarini Group's Obicetrapib Application Accepted by EMA for Cholesterol Treatment Menarini Group announces that EMA has accepted its applications for Obicetrapib and Obicetrapib/Ezetimibe to treat adults with primary hypercholesterolemia. This could revolutionize cholesterol management.

Menarini Group's Obicetrapib Application Accepted by EMA for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #Cholesterol_Treatment

Thiard News@F4F

@newsen.bsky.social

7 months ago

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Management The European Medicines Agency has accepted the application for Obicetrapib and its combination with Ezetimibe, marking a potential breakthrough in managing high cholesterol.

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Thiard News@F4F

@newsen.bsky.social

7 months ago

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Treatment Menarini Group's Obicetrapib and its combination with Ezetimibe have been accepted for review by the EMA for treating patients with high cholesterol.

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Thiard News@F4F

@newsen.bsky.social

7 months ago

Menarini Group's Obicetrapib Gains EMA Review for Cholesterol Treatment Menarini Group's Obicetrapib, a CETP inhibitor, receives EMA consideration to treat hypercholesterolemia, potentially helping patients not meeting LDL goals.

Menarini Group's Obicetrapib Gains EMA Review for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Thiard News@F4F

@newsen.bsky.social

7 months ago

Menarini Group's Obicetrapib and Ezetimibe Await EMA Approval for Cholesterol Management Menarini Group's applications for Obicetrapib and Ezetimibe have been accepted for review by the EMA, offering new hope for cholesterol management.

Menarini Group's Obicetrapib and Ezetimibe Await EMA Approval for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Thiard News@F4F

@newsen.bsky.social

7 months ago

Menarini Group's Obicetrapib Receives EMA's Review for Cholesterol Management The European Medicines Agency has accepted Menarini's application for Obicetrapib, a potential first-in-class CETP inhibitor, aimed at improving cholesterol management in adults.

Menarini Group's Obicetrapib Receives EMA's Review for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Thiard News@F4F

@newsen.bsky.social

10 months ago

Menarini Group Unveils Updated Findings on Elacestrant for Metastatic Breast Cancer at ASCO 2025 Menarini Group and Stemline Therapeutics present new data showcasing the efficacy of Elacestrant in treating ER+, HER2- metastatic breast cancer at ASCO 2025.

Menarini Group Unveils Updated Findings on Elacestrant for Metastatic Breast Cancer at ASCO 2025 #Italy #ORSERDU #Elacestrant #Florence #Menarini_Group

Thiard News@F4F

@newsen.bsky.social

10 months ago

Menarini Group Unveils Promising Elacestrant Data at ASCO 2025 Annual Meeting Menarini Group showcases updated data on Elacestrant's effectiveness in treating ER+, HER2- metastatic breast cancer, highlighting its potential for combination therapy at ASCO 2025.

Menarini Group Unveils Promising Elacestrant Data at ASCO 2025 Annual Meeting #USA #Elacestrant #Florence #Menarini_Group #ASCO_2025

Thiard News@F4F

@newsen.bsky.social

10 months ago

Menarini Group Showcases Latest Efficacy Data for Elacestrant in Breast Cancer at ASCO 2025 Menarini Group unveiled promising efficacy and safety data for Elacestrant combined with targeted therapies for ER+/HER2- metastatic breast cancer at ASCO 2025.

Menarini Group Showcases Latest Efficacy Data for Elacestrant in Breast Cancer at ASCO 2025 #Italy #Elacestrant #Florence #Menarini_Group #ASCO_2025

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Partners with VisualDx to Enhance BPDCN Diagnosis with AI Tools Menarini Group teams up with VisualDx to advance the diagnosis of BPDCN through innovative AI-driven methods, reshaping treatment paths for patients.

Menarini Group Partners with VisualDx to Enhance BPDCN Diagnosis with AI Tools #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Teams Up with VisualDx to Improve BPDCN Diagnosis and Early Detection Menarini Group and VisualDx collaborate to enhance the identification of those possibly affected by BPDCN, utilizing advanced AI technology for effective diagnosis.

Menarini Group Teams Up with VisualDx to Improve BPDCN Diagnosis and Early Detection #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group and VisualDx Join Forces to Enhance BPDCN Detection with AI Technology The Menarini Group collaborates with VisualDx to improve identification of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) using AI tools, enhancing early diagnosis.

Menarini Group and VisualDx Join Forces to Enhance BPDCN Detection with AI Technology #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini and VisualDx Join Forces to Enhance BPDCN Diagnosis with AI Technology Menarini Group partners with VisualDx to enhance early detection of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) using AI. This collaboration aims to improve patient outcomes through innovative medical technologies.

Menarini and VisualDx Join Forces to Enhance BPDCN Diagnosis with AI Technology #Italy #Florence #Menarini_Group #VisualDx #BPDCN

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Partners with Insilico Medicine for Innovative Oncology Solution Menarini and Insilico Medicine have finalized a second licensing agreement focusing on an AI-discovered oncology treatment, addressing significant unmet medical needs.

Menarini Group Partners with Insilico Medicine for Innovative Oncology Solution #USA #Florence #Menarini_Group #Insilico_Medicine #Stemline_Therapeutics

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini and Insilico Medicine Collaborate on New Oncology Drug Development Using AI Technology Menarini Group announces a second global license agreement with Insilico Medicine for an AI-developed oncology drug targeting unmet needs, enhancing cancer treatments.

Menarini and Insilico Medicine Collaborate on New Oncology Drug Development Using AI Technology #Italy #oncology #Florence #Menarini_Group #Insilico_Medicine

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini and Insilico Medicine Collaborate on AI-Driven Preclinical Oncology Asset Menarini Group and Insilico Medicine have executed a global license agreement for an AI-discovered preclinical oncology asset, aiming to tackle significant unmet medical needs.

Menarini and Insilico Medicine Collaborate on AI-Driven Preclinical Oncology Asset #Italy #oncology #Florence #Menarini_Group #Insilico_Medicine

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Expands Oncology Portfolio with New AI-Driven Licensing Partnership Menarini Group has secured a second exclusive global licensing agreement with Insilico Medicine for a promising preclinical oncology asset, marking a significant development in cancer treatment.

Menarini Group Expands Oncology Portfolio with New AI-Driven Licensing Partnership #USA #oncology #Menarini_Group #Insilico_Medicine #Florence,_Italy;_Cambridge,_Massachusetts

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group and Insilico Medicine Expand Collaboration with New AI-Driven Oncology License Menarini Group has secured a second exclusive global license from Insilico Medicine for an AI-discovered preclinical oncology asset. This deal has the potential to address urgent medical needs in cancer treatment.

Menarini Group and Insilico Medicine Expand Collaboration with New AI-Driven Oncology License #Italy #Florence #Menarini_Group #Insilico_Medicine #Oncology_Treatment